Sharon A Chung

List of Publications by Year
in descending order

43	3,923	257101 24	276539 41
papers	citations	h-index	g-index

44	44	44	4799
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Reply. Arthritis and Rheumatology, 2022, 74, 545-546.	2.9	0
2	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Care and Research, 2022, 74, 538-548.	1.5	13
3	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis and Rheumatology, 2022, 74, 586-596.	2.9	13
4	Endovascular Therapy for Intracranial Giant Cell Arteritis. Clinical Neuroradiology, 2022, , 1.	1.0	4
5	Dynamics of Methylation of <scp>CpG</scp> Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort. Arthritis and Rheumatology, 2022, 74, 1676-1686.	2.9	5
6	Sequenceâ€Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. Arthritis and Rheumatology, 2021, 73, 512-519.	2.9	34
7	Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Metaâ€Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 101-110.	0.9	12
8	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	2.6	26
9	Takayasu Arteritis: a Systematic Review and Metaâ€Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 80-90.	0.9	9
10	Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 91-100.	0.9	6
11	Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Metaâ€Analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 196-205.	0.9	10
12	Giant Cell Arteritis: A Systematic Review and Metaâ€Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 429-441.	0.9	20
13	Neurological manifestations of polyarteritis nodosa: a tour of the neuroaxis by case series. BMC Neurology, 2021, 21, 205.	0.8	3
14	Kawasaki Disease: A Systematic Review and Metaâ€Analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 671-683.	0.9	2
15	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis Care and Research, 2021, 73, 1088-1105.	1.5	90
16	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2021, 73, 1366-1383.	2.9	249
17	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis and Rheumatology, 2021, 73, 1349-1365.	2.9	231
18	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis and Rheumatology, 2021, 73, 1384-1393.	2.9	32

#	Article	IF	Citations
19	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Care and Research, 2021, 73, 1061-1070.	1.5	15
20	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care and Research, 2021, 73, 1071-1087.	1.5	61
21	A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nature Communications, 2019, 10, 3902.	5.8	39
22	149â€...Network-based analysis of clinical and molecular data in a multiethnic lupus cohort identifies molecular associations with serological manifestations. , 2019, , .		0
23	The Right Frame. Journal of Hospital Medicine, 2019, 14, 246.	0.7	0
24	DNA methylation 101: what is important to know about DNA methylation and its role in SLE risk and disease heterogeneity. Lupus Science and Medicine, 2018, 5, e000285.	1.1	52
25	Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients. PLoS ONE, 2018, 13, e0199003.	1.1	46
26	Analysis of pulmonary features and treatment approaches in the COPA syndrome. ERJ Open Research, 2018, 4, 00017-2018.	1.1	71
27	Primary Angiitis of the Central Nervous System. Rheumatic Disease Clinics of North America, 2017, 43, 503-518.	0.8	24
28	Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue hypoxia and type 1 interferon responses. Lupus Science and Medicine, 2016, 3, e000183.	1.1	54
29	Current Treatment of Cryoglobulinemic Vasculitis. Current Treatment Options in Rheumatology, 2016, 2, 213-224.	0.6	5
30	Rare variants, autoimmune disease, and arthritis. Current Opinion in Rheumatology, 2016, 28, 346-351.	2.0	13
31	Genome-Wide Assessment of Differential DNA Methylation Associated with Autoantibody Production in Systemic Lupus Erythematosus. PLoS ONE, 2015, 10, e0129813.	1.1	51
32	Lupus Nephritis Susceptibility Loci in Women with Systemic Lupus Erythematosus. Journal of the American Society of Nephrology: JASN, 2014, 25, 2859-2870.	3.0	117
33	Differential Genetic Associations for Systemic Lupus Erythematosus Based on Antiâ€“dsDNA Autoantibody Production. PLoS Genetics, 2011, 7, e1001323.	1.5	206
34	Risk Alleles for Systemic Lupus Erythematosus in a Large Case-Control Collection and Associations with Clinical Subphenotypes. PLoS Genetics, 2011, 7, e1001311.	1.5	154
35	A Comprehensive Analysis of Shared Loci between Systemic Lupus Erythematosus (SLE) and Sixteen Autoimmune Diseases Reveals Limited Genetic Overlap. PLoS Genetics, 2011, 7, e1002406.	1.5	148
36	Microscopic Polyangiitis. Rheumatic Disease Clinics of North America, 2010, 36, 545-558.	0.8	106

#	Article	IF	Citations
37	High-Density SNP Screening of the Major Histocompatibility Complex in Systemic Lupus Erythematosus Demonstrates Strong Evidence for Independent Susceptibility Regions. PLoS Genetics, 2009, 5, e1000696.	1.5	109
38	European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 60, 2448-2456.	6.7	27
39	A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nature Genetics, 2009, 41, 1228-1233.	9.4	729
40	Advances in the use of biologic agents for the treatment of systemic vasculitis. Current Opinion in Rheumatology, 2009, 21, 3-9.	2.0	31
41	Specificity of the STAT4 Genetic Association for Severe Disease Manifestations of Systemic Lupus Erythematosus. PLoS Genetics, 2008, 4, e1000084.	1.5	180
42	Association of Systemic Lupus Erythematosus withC8orf13â€“BLKandITGAMâ€“ITGAX. New England Journal of Medicine, 2008, 358, 900-909.	13.9	848
43	PTPN22: Its role in SLE and autoimmunity. Autoimmunity, 2007, 40, 582-590.	1.2	77